
Black snakeroot, rattlesnake root, squawroot
Remifemin®, Menofem®, Klimadynon®
Obtained from root of the plant, black cohosh is used as a dietary supplement to relieve the symptoms of menopause and dysmenorrhea. Black cohosh has antiosteoporotic effects (8) and has been shown to enhance bone formation (9). Black cohosh alone (1) (2) (3) or in combination with other herbs (4), (5) has been shown in clinical studies to be effective in the treatment of menopausal symptoms, but data are conflicting (6) (31) (32) (36). Conclusions of a meta analysis indicate insufficient evidence to support use of black cohosh for menopausal symptoms (40).
Studies evaluating black cohosh to treat hot flashes from breast cancer treatment also yielded mixed results (10) (11) (12). Further supplementation with black cohosh did not enhance bone density, improve menopausal symptoms, or 10-year risk of coronary heart disease in early postmenopausal women (37).
In vitro studies show black cohosh decreases prostate cancer cell proliferation (14) and induces an apoptotic response in liver cells (21). However, it also increased the incidence of metastatic disease in mice (16). Whether it has similar effects in breast cancer patients is not well studied, although a retrospective observational study of breast cancer patients found that black cohosh enhanced disease-free survival (15).
Some studies indicate that black cohosh does not possess estrogenic activity. Until this is confirmed, patients with estrogen receptor-positive cancers should use caution when considering the use of black cohosh dietary supplements.
Hepatoxicity has been associated with use of black cohosh (34), but data are conflicting (39).
Patients should consult their physicians before using black cohosh supplements.
Black cohosh may have estrogenic effects, but there are conflicting data (23). Studies also showed that it has no effect on LH, FSH, prolactin, or estradiol (24). A black cohosh extract was shown to have antiproliferative and antiestrogenic effects in ER-negative cells. This suggests that black cohosh mediates its effects via an estrogen-independent pathway (25), possibly through HER-2 signaling (26).
Black cohosh increases the incidence of metastatic disease in mice (16). In another study, black cohosh repressed the expression of cyclin D1 and ID3, and inhibited proliferation of HepG2, p53 positive, liver cells (43).
Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment—results of a large-scale, controlled, observational study. Maturitas. Aug 20 2007;57(4):405-414.
A prospective, controlled open-label observational study of 6141 women was used to analyze the effect of Black cohosh alone (Remifemin®) or in conjunction with St. John's wort (Remifemin® plus) on menopausal symptoms. After 3 months, the participants' Menopause Rating Scale (MRS) and PSYCHE scores were determined, demonstrating that the menopause-relieving characteristics of black cohosh were enhanced by St. John's wort. However, because of the observational nature of the study, no placebo-controlled group was included.
Rebbeck TR, Troxel AB, Norman S, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer. Apr 1 2007;120(7):1523-1528.
The relationship between breast cancer risk and hormone-related supplement use, including black cohosh, was assessed in a population-based case-control study of 949 participants with breast cancer and 1524 control participants. Use of either black cohosh or Remifemin® was associated with a reduction in breast cancer risk. Future studies to analyze the putative chemopreventative effects of black cohosh are required.
Pockaj BA, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC. J Clin Oncol 2006;24:2836-41.
One hundred and thirty-two women with persistent hot flashes for at least one month were randomized to receive 20mg of black cohosh extract twice a day or placebo for four weeks. This was followed by a crossover period of four more weeks where women who initially received black cohosh were given placebo and vice versa. Participants maintained weekly diaries of symptoms including nausea, excessive sweating, chills, headache, nervousness etc. At the end of the study period, women who received black cohosh reported a 20% reduction in the hot flash score compared to a 27% decrease by women on placebo.
These data suggest that black cohosh is not superior to placebo in reducing hot flashes.
Bottom Line: There is some evidence that black cohosh is effective for menopausal symptoms. More research is needed.
It is not clear if black cohosh is beneficial for menopausal symptoms due to conflicting results from various studies. There is not enough evidence to support its anticancer effects in humans. Patients should use caution as liver failure has been reported from its use.
Menopausal symptoms
Most studies on black cohosh have been done in Europe using the German product Remifemin®.
In a trial of 152 women with a moderate degree of menopausal symptoms, one group received black cohosh (Remifemin®) two tablets twice a day and the other group received 1 tablet twice a day. In both groups menopausal symptoms improved significantly by the same amount. However, this trial lacks a true control group (receiving a placebo pill) with which to compare the effects seen with Remifemin®.
Hot flashes from breast cancer treatment
A randomized, controlled trial studied the effect of black cohosh on hot flashes in women who had finished breast cancer treatment. Forty-two women received black cohosh and 43 received a placebo pill twice a day for 2 months. Fifty-nine women were receiving treatment with tamoxifen as well. The black cohosh and placebo groups reported similar improvements in symptoms, although women taking black cohosh had a greater decrease in sweating. From these data alone, it cannot be determined whether black cohosh is an effective treatment of hot flashes. In addition, this study did not follow patients long-term to determine whether black cohosh is safe in estrogen receptor-positive (ER+) breast cancer patients.
Another randomized, controlled trial also studied the effect of black cohosh on hot flashes in premenopausal women who had finished breast cancer treatment and were undergoing tamoxifen therapy. Forty-six patients received tamoxifen and 90 women received tamoxifen as well as black cohosh for twelve months. Comparing the two groups, the researchers found that significantly more women receiving black cohosh were free of hot flashes and that women receiving black cohosh had significantly fewer severe hot flashes than those on tamoxifen alone.
Because it is still unclear whether black cohosh has estrogenic effects, women with estrogen receptor-positive (ER+) cancers should avoid this supplement.